The European Cannabis Report: 9th Edition

0 items - £0.00 0

The 9th Edition of the longest-standing annual report dedicated to Europe's evolving and dynamic legal cannabis market is now available for pre-order.

This report, endorsed by headline partner, Curaleaf Laboratories, amongst others, offers the most up-to-date insights and analysis on the evolution of 30 key cannabis markets across Europe, including: Germany, Switzerland, Czech Republic, the Netherlands and the UK.

It is an extensive examination of significant sectors and geographical areas within the European cannabis industry, drawing from numerous data sources, including Prohibition Partners’ own proprietary market sizing data and analysis.

The free-to-download version of the report does not include market sizing data and analysis. For market sizing data and analysis (2024-2028), please see the paid-for packages available.

Israeli Product & Market Sizing Dataset

£399

A product dataset that includes information on almost 1000 products (638 Flower products, 192 Oil products & 15 Pre-Roll products). For product data on Flowers, Oils and Pre-Rolls, the following information is included: Price, Characterisation, Marketer, THC % (High, Low, Average), CBD % (High, Low, Average), Series, Brand and Manufacturing Country.

The dataset also includes market sizing and patient population forecasts (2023-2027) for the Israeli market.

ADD TO CART

The European Cannabis Report: 9th Edition

European Medical Market Sizing & Analysis (2024-2028)

You will be provided with raw market sizing forecasts (spreadsheet format) for 30 European countries, broken down by year (2024-2028). This package also includes medical cannabis patient population forecasts for all 30 countries.

In addition, you will receive an exclusive version of The European Cannabis Report: 9th Edition that includes an in-depth analysis of the market size of the European market, including written and visual interpretations and analysis of Prohibition Partners’ proprietary market sizing data.

£949

Full European Market Sizing & Analysis - Medical, CBD & Adult-Use (2024-2028)

Raw market sizing forecasts (spreadsheet format) for all three legal markets in Europe (Medical, Adult-Use & CBD), broken down by year (2024-2028). This includes:

Medical Market Sizing - Raw medical market sizing forecasts (spreadsheet format) for 30 European countries, broken down by year (2024-2028). This package also includes medical cannabis patient population forecasts for all 30 countries.
Adult-Use Market Sizing - Raw adult-use market sizing forecasts (spreadsheet format) for adult-use markets in Germany, Switzerland and the Netherlands, broken down by year (2024-2028).
CBD Market Sizing - Raw CBD market sizing forecasts (spreadsheet format) for 29 European countries, broken down by year (2024-2028).

£1795

Full Market Sizing, Analysis & Market Intelligence Briefing Consultation

All of the above market sizing data and analysis plus a two-hour market intelligence briefing consultation, covering key findings from the report plus bespoke insights, with a senior Prohibition Partners analyst and co-author of the report.

£2695

Add To Cart

Overview

Medical

The medical cannabis industry in Europe is experiencing significant growth both in regulations and market expansion. The UK leads this growth, surpassing sales expectations due to high per-patient consumption. Germany is poised for substantial growth as a new law simplifies prescription and distribution processes. Regulatory strides across Europe include France's decision to integrate cannabis treatment into mainstream medical care by early 2025, Ukraine's legalisation of medical cannabis in February 2024, Greece treating its first patients, Portugal approving three new products, and Spain initiating public consultations for a medical cannabis framework. Despite slow progress in adult-use cannabis legislation, optimism remains high for medical cannabis in Europe.

Adult-Use

In 2024, adult-use cannabis has seen notable advancements in Europe's legal landscape. Malta marked its initial sales through non-profit cannabis associations, Germany legalised possession and home cultivation while also allowing cannabis associations, Switzerland expanded adult-use pilot studies, and the Netherlands initiated its controlled supply chain experiment, introducing regulated cannabis to coffeeshops. These milestones signify substantial progress and a shifting attitude towards cannabis among the public, authorities, and governments in Europe.

CBD

The European CBD industry faces regulatory stagnation, with Novel Food applications stalled at both EU and UK levels. Despite widespread use, ongoing court cases, seizures, and product bans within EU member states pose challenges. While CBD remains an approved cosmetic ingredient in the EU CosIng database, its extraction legality (seeds, stems, or flowers) varies by national regulations, contributing to market uncertainty.

Contents
Executive Summary
Medical Cannabis
- European Medical Cannabis at a Glance
- EU-Wide Medical Cannabis Initiative
- Germany
- UK
- Italy
- France
- Spain
- Greece
- Ukraine
- Financial and Business Overview
Adult-Use Cannabis
- Germany
- Switzerland
- Netherlands
- Malta
CBD
- Novel Foods - EU and UK
- Legal Status of CBD
- HHC
Market Sizing Analysis
- Medical Market
- Adult-Use Market
- CBD

Key Findings

Medical

The current rate of progress in medical cannabis in Europe is significant, from both a regulatory and a market growth perspective.

The UK is the primary driver of new growth, with sales of medical cannabis higher than expected due to unusually high consumption volumes on a per-patient basis.
Germany is also expected to soon see a marked growth in medical cannabis sales as the new cannabis law comes into effect. The new law in Germany will make it easier to prescribe, distribute and dispense medical cannabis, as restrictive controls on handling narcotic substances will no longer apply.
In France the decision to end the trial programme and normalise cannabis treatment within the general medical system has been made, with a timeline to do so set for early 2025.
Ukraine legalised medical cannabis treatment in February 2024, with the new framework set to be established by August 2024.
Spain published a draft decree and launched public consultations on its proposal for a medical cannabis framework in February 2024.
Italy’s medical cannabis market is seeing stable and adequate supply for the first time.

The estimated European medical cannabis market size in 2024 is €779 million.

Adult-Use

Adult-use cannabis in Europe has seen significant strides made over the past year, with the legal landscape incrementally shifting towards legalisation.

The first pillar of Germany’s adult-use cannabis legalisation came into effect on April 1st 2024, removing cannabis from narcotics scheduling, and allowing members of the public to possess, cultivate and consume cannabis legally.
The first phase of the controlled cannabis supply chain experiment in the Netherlands kicked off in December 2023. Cannabis from the new regulated supply chains is now available in two municipalities, and will be the only cannabis available from all coffeeshops in ten municipalities by the end of 2024.
The Swiss system of pilot trials for adult-use cannabis continues to grow, with approximately 10,000 people currently sourcing cannabis from pharmacies legally. There are currently five trials underway, with two more due to begin in 2024, bringing the total number of participants up to 15,000.
The first sales by an operational not-for-profit cannabis association began in Malta in late January 2024, two years after the Maltese government decided to legalise adult-use cannabis.

The estimated European adult-use cannabis market size in 2024 is approximately €104 million.

CBD

The European CBD industry has been going through a long period of regulatory stagnation with Novel Food applications at the EU and the UK level seemingly at a standstill, with no clear signs of significant movement.

Court cases, seizures and bans of products ranging from flowers to oils within various EU member states still continue to haunt the CBD industry, although its wide use and distribution remains throughout the region.

The estimated market size of European CBD in 2024 is €1.97 billion.

European Medical Market Sizing & Analysis (2024-2028) - £949

Full Market Sizing & Analysis - Medical, CBD & Adult-Use (2024-2028) - £1,795

Raw market sizing forecasts (spreadsheet format) for all three legal markets in Europe (Medical, Adult-Use & CBD), broken down by year (2024-2028). This includes:

Medical Market Sizing - Raw medical market sizing forecasts (spreadsheet format) for 30 European countries, broken down by year (2024-2028). This package also includes medical cannabis patient population forecasts for all 30 countries.
Adult-Use Market Sizing - Raw adult-use market sizing forecasts (spreadsheet format) for adult-use markets in Germany, Switzerland and the Netherlands, broken down by year (2024-2028).
CBD Market Sizing - Raw CBD market sizing forecasts (spreadsheet format) for 29 European countries, broken down by year (2024-2028).

Full Market Sizing, Analysis & Market Intelligence Briefing Consultation (Medical, Adult-Use & CBD) - £2,695

As Trusted By

Insights

on the global cannabis industry

International Cannabis Weekly newsletter brings you the most important developments, news and informed commentary on the global cannabis industry. Join our community of 80,000+ subscribers.

The European Cannabis Report: 9th Edition

Israeli Product & Market Sizing Dataset

The European Cannabis Report: 9th Edition

Overview

Contents

Key Findings

European Medical Market Sizing & Analysis (2024-2028) - £949

Full Market Sizing & Analysis - Medical, CBD & Adult-Use (2024-2028) - £1,795

Full Market Sizing, Analysis & Market Intelligence Briefing Consultation (Medical, Adult-Use & CBD) - £2,695

As Trusted By

Insights

on the global cannabis industry